Evidence map›Paper›PMID 34707117›Full record

ArticleNPJ systems biology and applications2021

Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures.

Sepehr Golriz Khatami, Sarah Mubeen, Vinay Srinivas Bharadhwaj, Alpha Tom Kodamullil, Martin Hofmann-Apitius, Daniel Domingo-Fernández

Abstract read
In one paragraph

Article in NPJ systems biology and applications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Predicting drug outcome of population via clinical knowledge graph.medRxiv : the preprint server for health sciences · 2024
    Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sepehr Golriz KhatamiDepartment of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin, 53757, Germany. sepehr.golriz.khatami@scai.fraunhofer.de.ORCID http://orcid.org/0000-0002-7606-5228
Sarah MubeenDepartment of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin, 53757, Germany.ORCID http://orcid.org/0000-0002-9858-3755
Vinay Srinivas BharadhwajDepartment of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin, 53757, Germany.ORCID http://orcid.org/0000-0002-9901-9494
Alpha Tom KodamullilDepartment of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin, 53757, Germany.
Martin Hofmann-ApitiusDepartment of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin, 53757, Germany.ORCID http://orcid.org/0000-0001-9012-6720
Daniel Domingo-FernándezDepartment of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin, 53757, Germany. daniel.domingo.fernandez@scai.fraunhofer.de.ORCID http://orcid.org/0000-0002-2046-6145

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The utility of pathway signatures lies in their capability to determine whether a specific pathway or biological process is dysregulated in a given patient. These signatures have been widely used in machine learning (ML) methods for a variety of applications including precision medicine, drug repurposing, and drug discovery. In this work, we leverage highly predictive ML models for drug response simulation in individual patients by calibrating the pathway activity scores of disease samples. Using these ML models and an intuitive scoring algorithm to modify the signatures of patients, we evaluate whether a given sample that was formerly classified as diseased, could be predicted as normal following drug treatment simulation. We then use this technique as a proxy for the identification of potential drug candidates. Furthermore, we demonstrate the ability of our methodology to successfully identify approved and clinically investigated drugs for four different cancers, outperforming six comparable state-of-the-art methods. We also show how this approach can deconvolute a drugs' mechanism of action and propose combination therapies. Taken together, our methodology could be promising to support clinical decision-making in personalized medicine by simulating a drugs' effect on a given patient.

Indexed as

Biological PhenomenaMachine LearningAlgorithmsComputer SimulationHumansPrecision Medicine

Identifiers

PMID34707117
PMCPMC8551267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.